The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Genetically modified immunosuppresants. Buy the report here.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Genetically modified immunosuppressants is a key innovation area in pharmaceuticals
Genetically modified immunosuppressants are drugs that are genetically modified to suppress the immune system and decrease the body's ability to reject a transplanted organ.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 50 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of genetically modified immunosuppressants.
Key players in genetically modified immunosuppressants – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to genetically modified immunosuppressants
|Company||Total patents (2010 - 2022)||Premium intelligence on the world's largest companies|
|Takeda Pharmaceutical||137||Unlock Company Profile|
|Sangamo Therapeutics||104||Unlock Company Profile|
|Pluri||93||Unlock Company Profile|
|Bristol-Myers Squibb||73||Unlock Company Profile|
|Mesoblast||66||Unlock Company Profile|
|Athersys||39||Unlock Company Profile|
|Rubius Therapeutics||33||Unlock Company Profile|
|Celularity||32||Unlock Company Profile|
|Johnson & Johnson||28||Unlock Company Profile|
|Memorial Sloan Kettering Cancer Center||28||Unlock Company Profile|
|St. Jude Children’s Research Hospital||26||Unlock Company Profile|
|Daiichi Sankyo||22||Unlock Company Profile|
|Selecta Biosciences||22||Unlock Company Profile|
|SBI Holdings||22||Unlock Company Profile|
|Light Chain Bioscience||20||Unlock Company Profile|
|Hadasit Bio-Holdings||19||Unlock Company Profile|
|KYORIN Holdings||18||Unlock Company Profile|
|LG||17||Unlock Company Profile|
|Transimmune||16||Unlock Company Profile|
|Spanish National Research Council||16||Unlock Company Profile|
|Smith & Nephew||15||Unlock Company Profile|
|Priothera||14||Unlock Company Profile|
|Compugen||14||Unlock Company Profile|
|F. Hoffmann-La Roche||14||Unlock Company Profile|
|Garnet BioTherapeutics||14||Unlock Company Profile|
|Orbsen Therapeutics||13||Unlock Company Profile|
|Nippon Kayaku||13||Unlock Company Profile|
|Fred Hutchinson Cancer Research Center||12||Unlock Company Profile|
|Showa Denko||12||Unlock Company Profile|
|ReNeuron Group||12||Unlock Company Profile|
|Myelin Repair Foundation||12||Unlock Company Profile|
|PPF Group||11||Unlock Company Profile|
|General Hospital||10||Unlock Company Profile|
|Charles River Laboratories International||10||Unlock Company Profile|
|Erasmus MC||10||Unlock Company Profile|
|ImCyse||10||Unlock Company Profile|
|ImmuneMed||9||Unlock Company Profile|
|CoImmune||9||Unlock Company Profile|
|Massachusetts General Hospital||8||Unlock Company Profile|
|Stichting Sanquin Bloedvoorziening||7||Unlock Company Profile|
|Tocagen||7||Unlock Company Profile|
|Nagase & Co||7||Unlock Company Profile|
|UK Research and Innovation||7||Unlock Company Profile|
|CELLnLIFE||6||Unlock Company Profile|
|BioNTech||6||Unlock Company Profile|
|VivoscriptInc||6||Unlock Company Profile|
|Medeor Therapeutics||5||Unlock Company Profile|
|Enzo Biochem||5||Unlock Company Profile|
|Riken||5||Unlock Company Profile|
|Bambino Gesu Children’s Hospital||5||Unlock Company Profile|
Source: GlobalData Patent Analytics
Takeda is the leading patent holder for genetically modified immunosuppressants. The company has various immunosuppressants such as mezagitamab, which is currentlyin late-stage clinicaldevelopment. Monoclonal antibodies constitute the majority of products in its pipeline with immunosuppressive activity.
In terms of application diversity, Hadasit Bio-Holdings is the top company, followed by CELLnLIFE and BioNTech. By means of geographic reach, Myelin Repair Foundation holds the top position, while ReNeuron Group and ImCyse are in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.